First Quadrant’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

First Quadrant’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-19,500	Closed	-$215K	–	874
2016 Q1	$215K	Sell	19,500 -6,400	-25%	-$56.9K	﹤0.01%	566
2015 Q4	$238K	Sell	25,900 -65,800	-72%	-$551K	0.01%	543
2015 Q3	$636K	Buy	91,700 +28,200	+44%	+$241K	0.01%	429
2015 Q2	$624K	Buy	63,500 +33,700	+113%	+$307K	0.01%	442
2015 Q1	$264K	Buy	29,800 +25,300	+562%	+$202K	0.01%	508
2014 Q4	$39K	Sell	4,500 -37,000	-89%	-$299K	﹤0.01%	674
2014 Q3	$286K	Hold	41,500	–	–	0.01%	509
2014 Q2	$218K	Sell	41,500 -23,200	-36%	-$113K	﹤0.01%	565
2014 Q1	$294K	Hold	64,700	–	–	0.01%	496
2013 Q4	$326K	Sell	64,700 -35,300	-35%	-$170K	0.01%	505
2013 Q3	$507K	Sell	100,000 -28,100	-22%	-$156K	0.01%	456
2013 Q2	$635K	Buy	+128,100	New	+$610K	0.02%	410

Other funds holding SCLN

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Quadrant's SCLN Position: Q2 2016 in Review

First Quadrant sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2016, closing a stake of 19,500 shares — an estimated $215K sold.

First Quadrant first reported a position in SCLN in Q2 2013 and held it in 12 quarters. The position peaked at $636K in Q3 2015. 151 funds tracked by Wall St. Rank hold SCLN as of Q2 2016.

First Quadrant reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
First Quadrant sold 19,500 Sciclone Pharmaceuticals Inc shares in Q2 2016, an estimated $215K.
First Quadrant first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
First Quadrant's Sciclone Pharmaceuticals Inc position peaked at $636K in Q3 2015.
151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2016.

Based on First Quadrant's 13F filing for Q2 2016, filed 19 Jul 2016.